Current therapeutic strategies in adult acute lymphoblastic leukemia

Adele K Fielding

doi:10.1016/j.hoc.2011.09.008

Current therapeutic strategies in adult acute lymphoblastic leukemia

Adele K Fielding

The Hull York Medical School

Research output: Contribution to journal › Review article

Abstract

Approximately half of all adults with acute lymphoblastic leukemia now survive long term. This article summarizes the current approaches to treating acute lymphoblastic leukemia in adults, with a focus on a pragmatic approach to decision making. Coupled with a particularly punishing and often complex combination chemotherapy treatment regimen, treatment-related morbidity and mortality are frequent, and this article focuses on these situations. The field will change significantly over the next few years with many ongoing clinical studies and molecular insights which will be translated into providing prognostic information and novel therapeutic targets.

Original language	English
Pages (from-to)	1255-79, viii
Journal	Hematology/oncology clinics of North America
Volume	25
Issue number	6
DOIs	https://doi.org/10.1016/j.hoc.2011.09.008
Publication status	Published - Dec 2011

Bibliographical note

Keywords

Adult
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Hematopoietic Stem Cell Transplantation
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
Prognosis
Recurrence

Access to Document

10.1016/j.hoc.2011.09.008

Cite this

@article{c9c04f9cd2ab457ca96cab550b52294c,

title = "Current therapeutic strategies in adult acute lymphoblastic leukemia",

abstract = "Approximately half of all adults with acute lymphoblastic leukemia now survive long term. This article summarizes the current approaches to treating acute lymphoblastic leukemia in adults, with a focus on a pragmatic approach to decision making. Coupled with a particularly punishing and often complex combination chemotherapy treatment regimen, treatment-related morbidity and mortality are frequent, and this article focuses on these situations. The field will change significantly over the next few years with many ongoing clinical studies and molecular insights which will be translated into providing prognostic information and novel therapeutic targets.",

keywords = "Adult, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Hematopoietic Stem Cell Transplantation, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis, Prognosis, Recurrence",

author = "Fielding, {Adele K}",

year = "2011",

month = dec,

doi = "10.1016/j.hoc.2011.09.008",

language = "English",

volume = "25",

pages = "1255--79, viii",

journal = "Hematology/oncology clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "6",

}

TY - JOUR

T1 - Current therapeutic strategies in adult acute lymphoblastic leukemia

AU - Fielding, Adele K

PY - 2011/12

Y1 - 2011/12

N2 - Approximately half of all adults with acute lymphoblastic leukemia now survive long term. This article summarizes the current approaches to treating acute lymphoblastic leukemia in adults, with a focus on a pragmatic approach to decision making. Coupled with a particularly punishing and often complex combination chemotherapy treatment regimen, treatment-related morbidity and mortality are frequent, and this article focuses on these situations. The field will change significantly over the next few years with many ongoing clinical studies and molecular insights which will be translated into providing prognostic information and novel therapeutic targets.

AB - Approximately half of all adults with acute lymphoblastic leukemia now survive long term. This article summarizes the current approaches to treating acute lymphoblastic leukemia in adults, with a focus on a pragmatic approach to decision making. Coupled with a particularly punishing and often complex combination chemotherapy treatment regimen, treatment-related morbidity and mortality are frequent, and this article focuses on these situations. The field will change significantly over the next few years with many ongoing clinical studies and molecular insights which will be translated into providing prognostic information and novel therapeutic targets.

KW - Adult

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis

KW - Prognosis

KW - Recurrence

U2 - 10.1016/j.hoc.2011.09.008

DO - 10.1016/j.hoc.2011.09.008

M3 - Review article

C2 - 22093586

SN - 0889-8588

VL - 25

SP - 1255-79, viii

JO - Hematology/oncology clinics of North America

JF - Hematology/oncology clinics of North America

IS - 6

ER -